Table of Contents
Overview
New York, NY – May 30, 2025 – Global Colorectal Cancer Screening Market size is expected to be worth around US$ 31.1 billion by 2034 from US$ 15.5 billion in 2024, growing at a CAGR of 7.2% during the forecast period 2025 to 2034.
In 2024, the global colorectal cancer screening market witnessed notable growth, driven by the rising incidence of colorectal cancer and increased emphasis on early detection. Colorectal cancer ranks among the leading causes of cancer-related deaths worldwide, and timely screening is considered a key preventive strategy to reduce mortality.
Government-led awareness campaigns, improved reimbursement policies, and the adoption of non-invasive screening methods such as fecal immunochemical tests (FIT) and multi-target stool DNA tests have positively impacted market uptake. According to the World Health Organization (WHO), colorectal cancer accounted for nearly 1.9 million new cases globally in 2022, underscoring the importance of routine screening for individuals aged 50 and above, and those with genetic predispositions.
The integration of artificial intelligence (AI) in colonoscopy procedures and the growing use of telemedicine for pre-screening assessments have further enhanced accessibility and efficiency. Additionally, national screening programs across countries like the United States, Canada, the United Kingdom, and Australia have established a structured framework for early diagnosis.
The market is expected to continue expanding, supported by technological innovation, increased healthcare funding, and rising public-private partnerships. As early detection remains crucial to improving patient outcomes, colorectal cancer screening is projected to remain a priority in global healthcare policy and practice.
Key Takeaways
- In 2023, the colorectal cancer screening market generated a revenue of US$ 15.5 billion, and it is projected to reach US$ 31.1 billion by 2033, registering a CAGR of 7.2% during the forecast period.
- Colonoscopy dominated the screening tests segment in 2023, accounting for a 40.7% market share, followed by stool tests, flexible sigmoidoscopy, and other methods.
- By end user, hospitals held the largest share at 55.2% in 2023, reflecting their central role in large-scale screening programs and diagnostic services.
- North America emerged as the leading regional market, capturing 40.1% of the global revenue in 2023, supported by advanced healthcare infrastructure, established screening guidelines, and high awareness levels.
Segmentation Analysis
By Screening Tests Analysis: In 2023, the colonoscopy segment dominated the colorectal cancer screening market with a 40.7% share. This dominance is attributed to its effectiveness in detecting both cancer and precancerous polyps. As the gold standard, colonoscopy enables direct visualization and removal of lesions. The increasing prevalence of colorectal cancer, enhanced imaging technologies, and growing public awareness especially among individuals aged 50 and above are expected to sustain strong demand for colonoscopy in preventive screening protocols worldwide.
By End-User Analysis: Hospitals accounted for 55.2% of the market share in 2023, positioning them as the leading end-users of colorectal cancer screening services. Their capacity to offer integrated care including screening, diagnosis, and treatment supports their dominance. Advanced infrastructure, skilled personnel, and access to cutting-edge technologies further strengthen their role. Rising colorectal cancer incidence and expanding national screening initiatives are anticipated to drive more individuals to hospitals, reinforcing their position as key centers for early detection and cancer prevention efforts.
Market Segments
By Screening Tests
- Stool Tests
- Colonoscopy
- Flexible Sigmoidoscopy
- Others
By End-user
- Hospitals
- Specialty Clinics
- Others
Regional Analysis
In 2023, North America led the colorectal cancer screening market, accounting for 40.1% of global revenue. This dominance is attributed to a high disease burden, technological advancements, and strong awareness of early detection. According to the American Cancer Society, 153,020 people in the U.S. were diagnosed with colorectal cancer, with 52,550 reported deaths. These figures emphasize the urgent need for early screening. The adoption of non-invasive screening methods such as fecal immunochemical tests (FIT) and blood-based tests has improved accessibility. Updated screening guidelines recommending screening from age 45 have also contributed to market expansion.
Asia Pacific is projected to register the highest CAGR during the forecast period. Rising colorectal cancer incidence, especially among populations aged 40–44, highlights the need for expanded screening programs. For instance, Japan reported 26.7 cases per 100,000 men and 22.7 per 100,000 women in this age group. Increasing healthcare investment, greater public awareness, and a shift toward preventive care are driving demand for cost-effective, non-invasive screening methods. Government initiatives and improved diagnostic capabilities are expected to accelerate growth across the region.
Emerging Trends
- Expansion of Mailed Stool-Based Testing: Mailed stool testing programs have grown in reach. Uptake at federally qualified health centers has improved. These programs send kits directly to homes. They require minimal patient effort. Screening rates rise when reminders are used. Participation gains help reduce late-stage diagnoses. Cost-effectiveness analyses support wider implementation. This approach can close gaps in underserved areas. It also lowers barriers related to travel or clinic visits. The expansion of these programs can be attributed to supportive public health funding and simplified logistics.
- Growing Adoption of Stool DNA Tests: Stool DNA testing accounts for an increasing share of home-based screening. In 2023, 11.1 percent of adults used fecal DNA tests. These assays detect traces of tumor DNA in samples. They offer higher sensitivity than traditional fecal occult blood tests. Results can be mailed back to labs without office visits. Positive findings prompt follow-up colonoscopy. Patients report ease of use and clear instructions. Healthcare systems are integrating these options into screening guidelines. Adoption is driven by patient preference for non-invasive methods.
- Uptick in CT Colonography: CT colonography use has shown modest growth. In 2023, it represented 2.5 percent of all screening tests. This “virtual colonoscopy” uses low-dose CT scans. It requires bowel preparation but no sedation. Radiologists reconstruct three-dimensional images to detect polyps. Patients resume normal activities immediately after. Follow-up colonoscopy is required for positive findings. The technique appeals to those avoiding invasive procedures. Expanded insurance coverage supports its modest uptake. Accuracy and patient satisfaction are under continuous evaluation.
- Screening Among Younger Adults: CRC incidence is rising in younger age groups. Rates among those aged 15–39 climbed 3.8 percent per year. This increase has prompted guideline updates lowering the start age to 45. Early screening targets individuals with family history or risk factors. Public health campaigns now emphasize awareness in younger cohorts. Clinics have tailored outreach to adults in their 40s. Heightened vigilance aims to detect early-onset cases. Data monitoring continues to guide policy adjustments and resource allocation.
Use Cases
- Home-Based Stool Testing for Average-Risk Adults: Home-based testing suits adults aged 50–75 at average risk. In 2023, 12.8 percent of up-to-date screenings were home-based. Tests include FIT and stool DNA assays. Kits arrive by mail with clear instructions. Users collect samples and mail them to certified labs. Labs process results within days. Positive results trigger referral for colonoscopy. This model reduces clinic visits and increases reach. It is especially beneficial for rural or mobility-limited patients. Home-based testing supports goals like the Healthy People 2030 target of 74.4 percent screening coverage.
- Colonoscopy as the Gold Standard: Colonoscopy remains the most used modality for CRC screening. In 2023, 62.8 percent of adults reported colonoscopy or sigmoidoscopy. It allows direct visualization and polyp removal in one session. Patients undergo bowel prep and sedation. The procedure takes 20–60 minutes. Findings are reported within a week. It is recommended every ten years for average risk. Insurance plans typically cover screening colonoscopy fully. Its high accuracy makes it the reference standard. Resource planning ensures sufficient endoscopy capacity in major centers.
- Targeted Screening in Community Health Centers: Federally qualified health centers deploy tailored screening programs. They use mailed FIT kits and on-site education. Screening uptake has improved by up to 20 percent with these interventions. Centers serve populations with low prior screening rates. Staff provide culturally appropriate materials and reminders. Data tracking monitors follow-up colonoscopy completion. Partnerships with labs and endoscopy suites streamline care. These efforts help reduce disparities in CRC outcomes. Best practices are shared through CDC’s Cancer Prevention and Control Network.
Conclusion
By Screening Tests Analysis: In 2023, colonoscopy led the screening tests segment with a 40.7% market share. It remains the gold standard for detecting colorectal cancer and precancerous polyps through direct visualization and removal in one procedure. Growing public awareness, increased cancer prevalence, and improvements in imaging technologies continue to drive its demand. Individuals aged 50 and older, particularly those at higher risk, are the primary candidates for routine colonoscopy as part of national screening guidelines.
By End-User Analysis: Hospitals accounted for 55.2% of the market share in 2023, positioning them as the dominant end-user segment. Their capacity to deliver full-spectrum care from screening to diagnosis and treatment—makes them central to colorectal cancer screening programs. Equipped with advanced technologies and skilled professionals, hospitals remain the preferred setting for colonoscopies and follow-up care. Rising case numbers and expanded screening initiatives are expected to further drive patient volumes toward hospital-based services.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
